Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed follow...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Annals of translational medicine Ročník 7; číslo 5; s. 106
Hlavní autori: Bender, Laura, Meyer, Guillaume, Quoix, Elisabeth, Mennecier, Bertrand
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: China 01.03.2019
Predmet:
Anaplastic lymphoma kinase rearrangement (ALK rearrangement)
diffuse interstitial pneumonitis
ceritinib
non-small cell lung cancer (NSCLC)
ISSN:2305-5839, 2305-5839
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Bibliografia:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2305-5839
2305-5839
DOI:10.21037/atm.2019.01.24